Predicate |
Object |
assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_69ece09bafee7e0c49d1f7951a3faa2c |
classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-505 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-76 |
classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-2818 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-2827 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-39558 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06 |
classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-395 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K45-06 |
filingDate |
2015-12-04-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_54f6853ee7df612f25f83dede5f14b28 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_7616e1bd2487be1bc1b78258d9b0ba4b http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_5797678c63848fb26746e9718cc582b4 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e1df5eb3c888ab241446cb9de703c08e |
publicationDate |
2016-06-09-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationNumber |
US-2016158360-A1 |
titleOfInvention |
Methods and compositions for treating cancer using pd-1 axis antagonists and hpk1 antagonists |
abstract |
Compositions and methods for enhancing an immune response and treating cancer are provided. Compositions comprise PD-1 axis antagonists and HPK1 antagonists. PD-1 axis antagonists include PD-1 antagonists, PD-L1 antagonists, and PD-L2 antagonists. PD-1 axis antagonists can inhibit the binding of PD-L1 and/or PD-L2 to PD-1. HPK1 antagonists include compounds that inhibit the serine/threonine kinase activity of HPK1. Methods for enhancing an immune response or treating cancer comprise administering a PD-1 axis antagonist and a HPK1 antagonist, sequentially or simultaneously, to a subject in need thereof. |
isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-110404067-A http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2019057102-A1 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2019206049-A1 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2019164870-A1 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2022089225-A1 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2018081531-A2 |
priorityDate |
2014-12-05-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
type |
http://data.epo.org/linked-data/def/patent/Publication |